Across TCGA pan-cancer cohorts, PROZ Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PROZ data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PROZ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PROZ expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
BRCA, UCEC, and COAD are the cancer types where PROZ Mutation most reproducibly stratifies survival.